Federal award (DEFINITIVE CONTRACT, fiscal year 2021)
Recipient: POP BIOTECHNOLOGIES INC
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2019-06-17 to 2022-06-16
Current total value of award: $599897
Description: EO14042: THE OBJECTIVE OF THIS CONTRACT IS TO UTILIZE A NEXT-GENERATION VACCINE ADJUVANT THAT INDUCES RAPID AND SERUM-STABLE SPONTANEOUS NANOLIPOSOME-ANTIGEN PARTICLEIZATION IN COMBINATION WITH MULTIPLE NATIVE FLEXIBLY LINKED (NFL) HIV ENVELOPE TRIME